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Virus suppressionCD8+ T lymphocytes (CTL) play a role in controlling HIV/SIV infection. CTL antiviral activity is dependent on
recognition of antigenic peptides associated with MHC class I molecules on infected target cells, and CTL
activation can be impaired by Nef-mediated down-regulation of MHC class I molecules. We tested the ability
of a series of rhesus macaque CD8+ T-cell clones speciﬁc for the SIV Gag CM9 peptide to suppress SIV infection
of autologous CD4+ Tcells. We used a set of SIVmac239 viruses with either wild-type Nef or Nef mutations that
impair MHC class I down-regulation. All CTL clones efﬁciently suppressed virus replication in cells infected
with mutant viruses with altered Nef function, phenotypically MHC class Ihigh or MHC class Iintermediate.
However, the ability of the clones to suppress virus replication was variably reduced in the presence of wild-
type Nef (MHC class Ilow) despite the observations that all CTL clones showed similar IFN-γ responses to
titrated amounts of cognate peptide as well as to SIV-infected cells. In addition, the CTL clones showed variable
CD107a (CTL degranulation marker) responses that did not correlate with their capacity to suppress virus
replication. Thus, the clonal differences are not attributable to TCR avidity or typical effector responses, and
point to a potential as yet unknown mechanism for CTL-mediated suppression of viral replication. These data
emphasize that current assays for evaluating CTL responses in infected or vaccinated individuals do not fully
capture the complex requirements for effective CTL-mediated control of virus replication.© 2009 Elsevier Inc. All rights reserved.IntroductionMajor histocompatibility complex (MHC) class I-restricted CD8+ T
lymphocytes (CTL) are an important component of the immune
response following infection of humans with the human immunode-
ﬁciency virus (HIV) (Borrow et al., 1994; Froebel et al., 1994; Gruters,
van Baalen, and Osterhaus, 2002; Rowland-Jones et al., 2001) or non-
human primates (NHP) with simian immunodeﬁciency virus (SIV)
(Allen et al., 2002; Egan et al., 2000; Kuroda et al., 1999). Despite this
response, the immune system ultimately fails to control the virus and
virtually all untreated HIV-infected humans or SIV-infected rhesus
macaques eventually develop AIDS. Several mechanisms of viral
immune evasion and immune escape have been described, including
mutation of major CTL epitopes (Allen et al., 2004; Allen et al., 2000;
Barouch et al., 2002; Goulder et al., 2001; Johnson and Desrosiers,
2002; Leslie et al., 2004), impaired CTL responses due to upregulated
expression of inhibitory receptors (Day et al., 2006; Trautmann et al.,
2006) and loss of CD4+ T-cell help as a result of the direct cytopathic
effects of the virus (Gandhi et al.,1998; Sousa et al., 2002).While these
factors partly account for the lack of protection, alterations in the
levels of expression of key molecules in the virally-infected cellsll rights reserved.necessary for effective recognition and clearance by virus-speciﬁc CTL
seem to play an important role as well (Bell et al., 1998; Kestler et al.,
1991; Pennington et al., 1997; Xu et al., 1997). This protection from
CTL-mediated killing is thought to be mediated by a number of virus
gene products, especially the accessory protein, Nef (Kestler et al.,
1991; Kirchhoff et al., 1995; Rhodes et al., 2000).
Nef is a myristylated 27-kDa protein with diverse biological acti-
vities that include enhancement of viral particle infectivity and viral
replication (Kestler et al., 1991; Sugimoto et al., 2003). Nef has also
been shown to down-regulate the expression of a number of trans-
membrane molecules in host immune cells including the zeta chain of
the T-cell receptor (TCR) complex (Bell et al., 1998) andMHC class I on
Nef transfected human T-cell lines (Brenner et al., 2006; Mangasarian
et al., 1999; Munch et al., 2005; Schindler et al., 2004; Swigut et al.,
2000). Given the requirement for viral peptides to be in complex
withMHC class I molecules for virus-speciﬁc recognition by CD8+ CTL,
Nef-mediated down-regulation of MHC class I molecules on HIV/SIV-
infected cells might protect these cells from virus-speciﬁc CTL-
mediated killing, while not affecting MHC class I molecules inhibiting
NK cell-mediated lysis (Cohen et al., 1999; DeGottardi et al., 2008).
Indeed, deletions in the Nef gene have been correlated with protection
from progression to AIDS in HIV-infected individuals (Kirchhoff et al.,
1995; Oelrichs et al., 2000; Salvi et al., 1998) and SIV-infected rhesus
macaques (Kestler et al., 1991; Rud et al., 1994; Swigut et al., 2004).
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the poor replicative capacity of the Nef defective virus, better CTL
responses in the context of abolished MHC class I down-regulation, or
both is unknown. A number of studies have suggested that the direct
down-regulatory effect of HIV-1 Nef on MHC class I expression by
HIV-infected human cells is associated with signiﬁcant loss in the
virus suppressive capacity of HIV-1-speciﬁc CTL (Adnan et al., 2006;
Collins et al., 1998; Fujiwara and Takiguchi, 2007; Schwartz et al.,
1996; Tomiyama et al., 2002; Tomiyama et al., 2005; Ueno et al., 2008;
Yang et al., 2002). The effects of SIV Nef on MHC class I expression
have been mainly analyzed using human cell lines or whole human
PBMC (Brenner et al., 2006; Munch et al., 2005; Swigut et al., 2000).
Therefore, there is limited direct evidence of SIV Nef-mediated down-
regulation of MHC class I expression on SIV-infected primary NHP
CD4+ T cells (Sacha et al., 2007; Swigut et al., 2004) and its effect on
CTL-mediated suppression of SIV replication.
The SIV-rhesus macaque system is an important model for un-
derstanding the pathology and immune response/control of immu-
nodeﬁciency viruses. Therefore, the examination of SIV Nef-mediated
MHC class I down-regulation in primary NHP CD4+ T cells and its
impact on CTL-mediated recognition of virally-infected cells should
help in evaluating vaccine candidates eliciting virus-speciﬁc CTL
responses in NHP models of AIDS. To study this, we compared MHC
class I expression on rhesus CD4+ Tcells infectedwithwild-type (WT)
SIVmac239 (Nef/open) expressing a fully functional Nef (Kestler et al.,
1991), a natural truncation mutant SIVmac239 (Nef/stop) (Kestler
et al., 1991), or a series of engineered SIVmac239 viruses with different
mutations in the Nef sequence that alter its MHC class I down-
regulatory properties (Schindler et al., 2004). We further evaluated
the impact of different levels of MHC class I down-regulation
mediated by these viruses on the capacity of different SIV-speciﬁc
CTL clones, generated against the same Gag epitope, to suppress virus
replication in infected CD4+ Tcells. We found clonal differences in the
ability of different virus-speciﬁc CTL clones to suppress SIV replication
in target cells exhibiting Nef-mediated MHC class I down-regulation
that did not correlate with typical effector parameters.
Results
SIV Nef myristylation required for Nef-mediated MHC class I
down-regulation
To study the dynamics of SIV Nef, MHC class I expression and CTL-
mediated virus suppression in rhesus macaque T-cell cultures, we
constructed two Nef SIV mutants that modulated the function of
Nef. To eliminate Nef function but retain Nef expression for future
studies with CTL speciﬁc for Nef, we produced Nef/G2V that contains
a point mutation abolishing the myristylation of Nef, so that the
expressed Nef protein cannot associate with the plasma membrane.
The Nef/G2Vmutation has been reported to render Nef nonfunctional
when transfected into human T-cell lines (Schindler et al., 2004). The
Y223F mutation only affects the MHC class I down-regulatory
properties of Nef, allowing us to focus solely on this function and
rule out other properties of Nef (Schindler et al., 2004). Noteworthy,
Munch et al. reported rapid reversion of the Y223F mutant in infected
rhesus macaques (Munch et al., 2002). We also included the SIV Nef/
stop (truncated Nef) mutant virus in our study (Kestler et al., 1990;
Kestler et al., 1991), and examined the replication and Nef-mediated
MHC class I down-regulatory properties of these viruses in macaque
CD4+ T-cell clones (Fig. 1A).
Rhesus CD4+ T cells were infected with WT Nef/open, Y223F, G2V
or Nef/stop mutants, and MHC class I expression on the infected cells
was analyzed by ﬂow cytometry. We focused the analyses on infected
cells by gating on intracellular SIV Gag p27 positive cells at day 8 PI,
the time point with the highest frequency of SIV Gag p27 positive cells
(Minang et al., 2008). All viruses down-regulated CD4 surfaceexpression on infected cells and most of the viruses infected the
target cells to a similar degree by day 8 PI, except for the Nef/stop
mutant virus with approximately half as many Gag p27 positive cells
(Fig. 1B, representative experiment). We could not detect a difference
in the number of infected cells between the myristylation defective
G2V mutant virus and the WT or SIV Y223F mutant viruses. When
gating within the Gag p27 positive population, we observed similar
mean ﬂuorescence intensities for SIV Gag p27 staining for WT and
mutant virus-infected cells (data not shown), suggesting similar
amounts of Gag protein expression per infected cell by the WT and
mutant viruses. In addition, in a kinetic study we measured viral RNA
and Gag p27 levels in the cultures on a daily basis and could not detect
any consistent differences betweenWTand the Y223F or G2Vmutants
(data not shown). There was a marked decrease in MHC class I
expression on cells infected with WT SIV compared to the three
mutants (Fig. 1C, data from a representative experiment). By gating on
SIV Gag p27 positive cells in the infected cultures and all cells for the
uninfected cultures, and displaying MHC class I expression levels
using histograms, reproducible but subtle differences in MHC class I
expression levels between Nef/stop and Y223F or G2V mutant virus-
infected cells were revealed. MHC class I expression levels on cells
infected with WT virus was reduced ∼3 fold compared with cells
infected with virus lacking full length Nef expression (Nef/stop),
conﬁrming the role of SIV Nef in down-regulating MHC class I on
infected rhesus CD4+ T cells (Schindler et al., 2004; Swigut et al.,
2000). Cells infected with either the Y223F or G2V virus showed
intermediate MHC class I expression compared to WT and Nef/stop
(Fig. 1D, inserted color coded numbers). Overall, the SIV Y223F, G2V
and Nef/stop mutant virus-infected cells had higher MHC class I
expression levels than uninfected cells; possibly due to the elevated
protein-synthesis with increased generation of peptides in infected
cells, leading tomore stable expression ofMHC class I molecules (Rock
and Goldberg, 1999). Hence, except for the Nef/stop mutant, our Nef
mutant viruses replicate in CD4+ Tcells to essentially the same degree
as WT SIV, but do not down-regulate MHC class I relative to WT SIV.
CTL-mediated suppression of virus replication in SIV-infected CD4+
T cells is impaired by Nef-induced down-regulation of MHC
class I expression
We have previously described an in vitro assay for measuring CTL-
mediated SIV virus suppression (Minang et al., 2008). In a preliminary
screening of a number of SIV Gag CM9-speciﬁc CTL clones generated
from a SIVmac239-infected rhesus macaque, we found different levels
of suppression of WT SIV replication, ranging from no effect to more
than 100-fold suppression of virus production. We therefore investi-
gated if differences in the capacity to suppress viral replication by
these SIV Gag CM9-speciﬁc CTL clones were due to differences in their
sensitivity to Nef-mediated MHC class I down-regulation. CD4+ Tcells
infected with WT (MHC class I+/−) or the Y223F and G2V (both MHC
class I+++) or Nef/stop (MHC class I++++) viruses were co-cultured
with different autologous SIV Gag CM9-speciﬁc CTL clones at a CD8+:
CD4+ T-cell ratio of 1:1. Suppression of virus replication was assessed
by measuring the frequency of SIV Gag p27 positive cells by ﬂow
cytometry and the accumulated viral RNA levels in the supernatant
by quantitative RT PCR 8 days PI. As described previously, a CTL clone
was arbitrarily considered to inhibit viral replication in a co-culture
with infected cells when a reduction in viral RNA levels of at least 1 log
was observed in culture supernatants (Minang et al., 2008) and the
frequency of preserved CD4+ T cells as well as eliminated Gag p27
positive cells was at least 2-fold higher than in cultures of infected
cells alone.
In the absence of virus-speciﬁc CTL, all virus-infected cultures
showed massive loss of CD4+ T cells with greater than 30% of the
remaining cells positive for SIV Gag p27. Little or no CD4+ T-cell
preservationwas observed in co-cultures of WT SIV-infected cells and
Fig. 1. Schematic representation of SIV Nef gene sequence present in infectious molecular clone of SIVmac239. Nef reading frame of SIVmac239 begins at nucleotide 9348 and ends at
10,139 (numbering of Regier and Desrosiers (1990)). SIVmac239 Nef/stop contains a stop codon (TAA) at position 9624–9626, the 93rd codon of the gene leading to expression of a
nonfunctional truncated Nef peptide. SIVmac239 Nef/Y223F contains an A-to-T replacement at position 10,015 of the nucleic acid sequence leading to a tyrosine to phenylalanine
change at position 223 of the peptide sequence (Swigut et al., 2000). SIVmac239 Nef/G2V contains a G-to-T replacement at position 9352 of the nucleic acid sequence leading to a glycine
to valine change at position 2 of the peptide sequence (A). SIVmac239Nef/Y223F (Y223F) and Nef/G2V (G2V)mutant viruses infect, replicate andmediate CD4 downregulation in rhesus
macaque CD4+ T cells at levels comparable with WT virus in vitro. CD4+ T cells from a rhesus macaque were infected with molecularly cloned WT SIVmac239, Y223F, G2V or Nef/stop
mutant virus. The cells were cultured in 24-well tissue culture plates at 1×106 cells/well. The frequency of SIV Gag p27-expressing cells (B, C), CD4 (B) andMHC class I (C, D) expression
levels were determined on day 8 PI by ﬂow cytometry. Histograms representMHC class I expression levels on cells within the SIV Gag p27+ gate (from SIV-infected cultures) or on CD4+
cells (from uninfected cultures). Geometric mean ﬂuorescence intensities (GMFI) are shown. Plots are representative of 3 independent experiments.
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line with this, CM9-11 had no detectable impact on the frequency of
Gag p27 positive cells, taking into account the 1:1 CD8:CD4 cell ratios
at the start of the co-cultures (Fig. 2A). However, CM9-11 could
preserve CD4+ T cells and eliminated most Gag p27 positive cells in
Y223F, G2V and Nef/stop mutant virus-infected cultures. This
suggests a role of Nef-induced MHC class I down-regulation in
mediating resistance to virus control by CTL. In contrast to clone CM9-
11, a marked preservation of CD4+ T cells was observed in WT SIV-
infected cultures in the presence of CTL clones CM9-12 and -14. This
was accompanied by robust elimination ofmost or all Gag p27 positive
CD4+ T cells. Just as clone CM9-11, CM9-12 and -14 could efﬁciently
suppress viral replication when co-cultured with the Nef mutant
virus-infected cells.
The data on CD4+ T-cell preservation and Gag p27 positive cell
elimination was consistent with viral RNA data. Little or no difference
was observed in the viral RNA levels (b1 log reduction) in co-cultures
of cells infected withWT SIV (MHC class I+/−) and CM9-11 compared
to cultures of infected cells alone. On the other hand, ∼2 and 1.5-log
reductions in viral RNA levels were observed in co-cultures ofWT SIV-
infected cells and CM9-12 and -14, respectively (Fig. 2B). A greater
than 1-log reduction in viral RNA levels was observed in co-cultures of
all three CTL clones and the Y223F, G2V (both MHC class I+++) and
Nef/stop (MHC class I++++) mutant virus-infected cells. In line with
the reduced replicative capacity of the Nef/stopmutant virus, all three
CTL clones showed higher suppression of the Nef/stop mutant virus
compared to the Y223F and G2V mutants. Hence, SIV Nef-mediated
MHC class I down-regulation blunts the virus replication inhibitorycapacity of SIV-speciﬁc CTL, with a complete abrogation seen for
some clones.
Induction of IFN-γ and CD107a in SIV-speciﬁc CTL clones by SIV-infected
autologous CD4+ T cells is not associated with functional avidity or
ability to suppress virus
Lower levels of cell surface MHC class I would correspond to
reduced presented epitope density on the surface of infected cells, and
would be expected to result in preferential triggering of CTL cloneswith
TCRs having higher functional avidity for the MHC class I-peptide
complex. Having demonstrated clonal differences in the viral inhibitory
capacity of different CTL clones speciﬁc for the same SIV Gag CM9
epitope, we investigated if the clonal variability in CTL suppression of
WT SIV Nef/open replication was due to variable functional avidity
among the clones for the cognate peptide. An autologous B-cell line
pulsed with titered amounts of SIV Gag CM9 peptide or CD4+ T cells
infected with WT SIV (MHC class I+/−), Y223F, G2V (both MHC class
I+++) or Nef/stop mutant viruses (MHC class I++++) was used as
APC to stimulate the different SIV Gag CM9-speciﬁc CTL clones, and
IFN-γ expression and CD107a capture on the CTL clones was assessed
by ﬂow cytometry.
The three SIV-speciﬁc CTL clones; CM9-11, -12 and -14, showed
similar maximal levels and similar dose response curves for IFN-γ
expression following stimulation with APC pulsed with titered
amounts of the SIV Gag CM9 peptide (Fig. 3A). In addition, when
tested against more physiologically relevant APC, autologous CD4+ T
cells infected with WT SIV (MHC class I+/−), strong IFN-γ expression
Fig. 2. SIV Gag CM9-speciﬁc CTL clones display clonal differences in their capacity to inhibit replication ofWT SIVmac239 in autologous rhesus CD4+ T-cell clones. CD4+ Tcells infected
with molecularly clonedWT SIVmac239, Y223F, G2V or the Nef/stopmutant virus were co-cultured with autologous SIV Gag CM9-speciﬁc CTL clones, CM9-11, -12 and -14, in 24-well
tissue culture plates with 1×106 cells/well at a CD8+:CD4+ T-cell ratio of 1:1. The frequency of SIV Gag p27+ cells (A) and virion associated SIV gag RNA content of culture supernatant
(B) were determined 8 days PI by ﬂow cytometry and quantitative RT PCR, respectively. Uninfected target cells and infected CD4+ T cells cultured without CD8 effectors were included
as negative and positive controls, respectively. (A) is representative of 3 independent experiments and (B) means and standard deviations of two independent experiments.
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variable viral suppression properties, the frequencies of intracellular
IFN-γ positive cells as well as the levels of IFN-γ-expression per cell
(mean ﬂuorescence intensities; MFI) following stimulation were
similar for the three CTL clones (Fig. 3B; data not shown). As with
responses to the WT SIV-infected cells, there were no apparent
differences in the IFN-γ responses to Y223F- or G2V mutant virus-
infected cells (both MHC class I+++) between the three CTL clones
(Fig. 3B). All three CTL clones showed similar IFN-γ responses to cells
infected also with the poorly replicating SIV Nef/stop mutant virus,
indicating that the low number of SIV p27+ cells in these cultures was
still sufﬁcient to trigger the TCRs. Hence, the differential viral
suppressive capacities of the CTL clones cannot be accounted for by
any detectable differences in their functional avidity against cognate
peptide or infected cells as measured by their IFN-γ response.
Lymphocyte associated membrane protein 1 (LAMP-1; CD107a)
expression has been shown to directly correlate with CTL lytic capacity
as measured by a ﬂow cytometry-based killing assay (Betts et al.,
2003). Given our observation of a lack of direct association between
the frequency of SIV-infected cell-induced IFN-γ-expressing cells in
the virus-speciﬁc CTL clonal populations and their capacity to
suppress WT SIV replication, we also investigated if there was a
difference in CD107a capture on the cell surface, a marker of CTL lytic
capacity. All three SIV-speciﬁc CTL clones; CM9-11, -12 and -14,
showed a similar CD107a staining proﬁle in response to autologous
SIV-infected CD4+ T cells, and the frequency of the CD107a positive
cells within each clonal population did not correlate with the capacity
of the individual CTL clones to suppress WT SIV replication (Fig. 3C;
data from a representative experiment). The lowest frequency of
CD107a positive cells following stimulationwithWT SIV-infected cells
was seen with the CTL clone CM9-12, which showed the most robust
suppressive capacity against WT SIV replication. A similar patternwas
observed for responses to mutant virus-infected cells, with CM9-11and CM9-14 showing slightly higher frequencies of CD107a respond-
ing cells than CM9-12 (Fig. 3C). When the CD107a responses of the
three CTL clones to titrated amounts of cognate peptide were
analyzed, similar responses were observed (data not shown). Hence,
differences in lytic capacity, as measured by CD107a capture, could not
account for the clonal differences in viral suppression capacity
between the three SIV Gag CM9-speciﬁc CTL clones tested.
Subtle changes in levels of MHC class I expression have marked impact
on CTL-mediated viral suppression capacity
Given our observation that a 2–3 fold reduction in the expression
of MHC class I molecules on the surface of WT SIV Nef/open-infected
cells leads to a complete loss of virus suppression by the CTL clone
CM9-11, we investigated if a less pronounced level of MHC class I
down-regulation would still inhibit virus suppression by this CTL
clone. To accomplish this, we constructed an SIV mutant, Nef/RR137-
138AA (RR-AA; Fig. 4A), that induces a more moderate level of MHC
class I down-regulation in infected cells compared with WT SIV
(Schindler et al., 2004). Primary rhesus macaque CD4+ T cells were
infectedwithWT SIV, Y223F, G2V, Nef/stop or the RR-AAmutant virus
and MHC class I expression assessed on day 7 PI by ﬂow cytometry;
the RR-AA mutant virus-infected cells consistently showed MHC
class I expression at levels intermediate (MHC class I+) between WT
SIV (MHC class I+/−) and the Y223F and G2V mutants (both MHC
class I+++) (Figs. 4B and C; data from representative experiment).
Autologous CD4+ T cells infected with WT SIV (MHC class I+/−),
the G2V (MHC class I+++) and RR-AA (MHC class I+) mutant viruses
were then co-cultured with the CTL clone CM9-11 and viral RNA
levels in culture supernatant measured by RT PCR on day 8 PI. The
CM9-11 CTL clone which failed to suppress the replication of WT
SIV, consistently suppressed virus replication in CD4+ T cells infected
with the RR-AA mutant; N 1 log reduction in viral RNA with marked
Fig. 3. SIV Gag CM9 peptide-pulsed APC or CD4+ Tcells infected withWTor mutant SIV elicit IFN-γ and CD107a expression in SIV Gag CM9-speciﬁc CTL with high as well as low virus
suppression capacities. (A) Autologous herpesvirus papio-transformed B cells pulsed with 10-fold serial dilutions of the SIV Gag181–189CTPYDINQM (CM9) peptide (from 5 μg/mL
down to 10−5 μg/mL) and (B, C) CD4+ T cells infected with WT or mutant SIV were used as APC to stimulate different SIV Gag CM9-speciﬁc CTL clones, CM9-11, -12 and -14, in a 5 h
assay. The frequency of IFN-γ (A, B) and CD107a (C) positive cells were determined by ﬂow cytometry. (A) Means plus standard deviations for two independent experiments. (B, C)
Plots are representative of 3 independent experiments.
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cells (Fig. 4D; data not shown). We could not detect a consistent dif-
ference in sensitivity to suppression between CD4+ Tcells infectedwith
the RR-AA mutant compared with the G2V mutant. Thus, slightly
increasedMHCclass I expression on target cells, as seen on cells infected
with the RR-AA mutant compared with WT SIV virus is sufﬁcient to
overcome SIV Nef-induced resistance to CTL-mediated suppression.
Discussion
Here we report three main ﬁndings with important implications
for SIV/HIV immunobiology and HIV vaccine research: i) different SIV-
speciﬁc CTL clones speciﬁc for the same epitope mediating viral
suppression vary in their susceptibility to Nef-mediated MHC class I
down-regulation ii) this clonal difference seems to be independent of
functional avidity and iii) the difference is independent of IFN-γ
responses and CTL lytic potential against virus-infected CD4+ T cells.
A central paradox in HIV/SIV immunopathology is the ability of the
virus to continue to replicate and eventually overwhelm the immune
system despite robust virus-speciﬁc CTL activity as measured by
peptide-induced IFN-γ responses. While mutations in CTL epitopes is
a powerful mechanism of viral escape, down-regulation of MHC class I
by HIV-1 and SIV Nef has been proposed to protect infected cells by
blunting their recognition and eventual killing by virus-speciﬁc CTL
(Brenner et al., 2006; Collins et al., 1998; Munch et al., 2005; Sacha
et al., 2007; Schwartz et al., 1996; Swigut et al., 2004; Swigut et al.,
2000). Furthermore, data from both HIV-1 and SIV suggest that Nef
selectively down-regulates MHC class I loci engaged in presenting CTLpeptide epitopes, while not affecting expression of MHC class I loci
shown to protect from NK-mediated lysis (Cohen et al., 1999;
DeGottardi et al., 2008). In this report, we demonstrate that CTL-
mediated virus suppression is inhibited by SIV Nef-dependent MHC
class I down-regulation in SIV-infected primary rhesusmacaque CD4+
T cells. WT SIV Nef/open-infected cells showed varying degrees of
resistance to viral suppression by different SIV Gag-speciﬁc CTL
clones, with one clone unable to preserve CD4+ T cells or inhibit SIV
replication. Using SIV with different mutations in the Nef sequence;
Y223F that selectively affects the MHC class I down-regulatory effect
of Nef, and G2V, that has been described as rendering Nef nonfunc-
tional (Schindler et al., 2004), we found that all tested SIV Gag-speciﬁc
CTL clones preserved CD4+ T cells and inhibited the replication of the
Y223F and G2V mutant viruses. Thus, SIV Nef-mediated MHC class I
down-regulation can protect SIV-infected cells from CTL-mediated
suppression, and render some CTL clones unable to suppress viral
replication in vitro. To expand on our investigation on the differential
sensitivity of the CTL clones to Nef-mediated MHC class I down-
regulation, we engineered the SIVmac239 mutant virus, Nef/RR137-
138AA (RR-AA) (Schindler et al., 2004), which induced MHC class I
down-regulation in CD4+ T cells at levels close to but higher than WT
SIV. We hypothesized that the RR-AA mutant virus-infected cells
would present cognate viral peptides on their surface at levels in-
between WT SIV- and G2V mutant virus-infected cells and thus also
show intermediate susceptibility to SIV-speciﬁc CTL-mediated sup-
pression of viral replication. The CM9-11 CTL clone that failed to
suppressWT SIV suppressed replication of the RR-AA and G2Vmutant
viruses to a comparable degree. This suggests that subtle changes in
Fig. 4. Schematic representation of the Nef sequence in an engineered SIVmac239 Nef/RR137-138AAmutant virus. SIVmac239 Nef/RR137-138AA contains two AG-to-GC replacements
at positions 9756/9757 and 9759/9760 of the Nef nucleic acid sequence leading to an arginine–arginine to alanine–alanine change at positions 137 and 138 of the peptide sequence
(A). CD4+ Tcells infected with SIVmac239 Nef/RR137-138AA (RR-AA) mutant virus showMHC class I expression at levels intermediate betweenWT SIV- and Y223F, G2V or Nef/stop
mutant virus-infected cells. CD4+ T cells were infected with WT SIV, RR-AA, Y223F, G2V or Nef/stop mutant viruses and MHC class I expression levels determined 8 days PI by ﬂow
cytometry. Shown are dot plots for MHC class I levels versus SIV Gag p27 expression (B) and mean+SD of the geometric mean ﬂuorescent intensities (GMFI) of MHC class I
expression on cells within the SIV Gag p27+ gate (for SIV-infected cultures) or CD4+ cells (for uninfected cultures) (C); data are from 3 or 4 independent experiments and statistical
analyses ⁎ indicates p value b0.05 for WT versus G2V, Y223F and Nef/stop as well as for RR-AA versus Nef/stop. (D) Mutant RR-AA, G2V as well as WT virus have comparable
replicative capacities in rhesus CD4+ Tcells but have differential susceptibility to suppression by a Gag CM9-speciﬁc CTL clone, CM9-11. CD4+ Tcells infected withWT SIV, the RR-AA
or G2Vmutant virus were co-culturedwith CM9-11 at a CD8+:CD4+ T-cell ratio of 1:1 and viral RNA levels measured 8 days PI by quantitative RT PCR. Shown aremeans and standard
deviations of two independent experiments.
135J.T. Minang et al. / Virology 391 (2009) 130–139MHC class I expression levels on infected cells can markedly affect the
capacity of virus-speciﬁc CTL to suppress virus replication.
Interestingly, loss of myristylation has been reported to lead to a
complete loss of SIV Nef function (Schindler et al., 2004), while amore
subtle phenotype was reported by Chowers et al. (1994). In our model
using primary rhesus macaque CD4+ T cells, we observed similar
levels of CD4 down-regulation and viral replication after infection
withWT SIV and the G2Vmutant viruses. This is in contrast to the loss
of MHC class I down-regulatory effect by the G2V mutant. The lack of
detectable impact of the Nef/G2V mutation on SIV replication in a
primary rhesus CD4+ T-cell clone is intriguing. The discrepancy
between these previous studies and our data could be due to the fact
that we used SIV-infected primary CD4+ T cells while the above
studies used established human cell lines as targets. In a separate
study, we conﬁrmed similar replication kinetics and CD4 down-
regulatory effect between WT SIV and the G2V mutant virus in
primary rhesus CD4+ T cells but signiﬁcantly reduced replication of
the G2V mutant in a human T-cell line (manuscript in preparation)
suggesting that SIV Nef differentially affects SIV replication in human
cell lines and primary rhesus CD4+ T cells.
There were marked clonal differences in the abilities of clones
having the same speciﬁcity to suppress replication in the context of
MHC class I down-regulation. These differences were not attributable
to TCR avidity as assessed by IFN-γ expression by the CTL clones
following stimulation with APC pulsed with tittered amounts of
peptide; IFN-γ response curves of the clones were nearly identical.
This is in agreement with other reports showing similar IFN-γ
responses to cognate peptide-pulsed APC by CTL clones speciﬁc for
different SIV epitopes despite substantial differences in their viralsuppressive capacities (Betts et al., 2003; Chung et al., 2007). A
number of studies have suggested an epitope-dependent effect of
HIV-1 Nef on the ability of HIV-1-speciﬁc CTL to suppress HIV-1
replication (Adnan et al., 2006; Tomiyama et al., 2005; Yang et al.,
2003). We tested and compared several clones speciﬁc for the same
SIV Gag epitope; CM9. Experiments with CTL clones speciﬁc to the SIV
Nef165–173IW9 and Tat28–35SL8 epitopes using WT SIV and the G2V
mutant virus yielded similar results i.e. clonal differences in the viral
suppressive capacity of the CTL clones speciﬁc to the same epitope
(data not shown). In contrast to the studies with HIV-1, our data show
clear clonal differences in antiviral capacity between SIV-speciﬁc CTL
clones sharing the same speciﬁcity. To further investigate any
potential differences in functional avidity between the CTL clones,
we assessed IFN-γ expression and CD107a capture following stimula-
tion with SIV-infected CD4+ T cells, a more physiologically relevant
target. Surprisingly, similar frequencies of IFN-γ-producing cells were
seen in the three CTL clones following stimulation with autologous
SIV-infected CD4+ T cells. Similar to the IFN-γ responses to virus-
infected CD4+ Tcells, surface caption of the CTL degranulationmarker
CD107a by the three tested CTL clones was not associated with their
capacity to suppress SIV replication. Measurement of CD107a capture
is used as a marker of antigen speciﬁc CD8+ CTL degranulation
capacity (Betts et al., 2003; Dunham et al., 2006; Gauduin et al., 2006).
Virus-speciﬁc CTL-mediated virus control has been suggested to
involve a direct killing mechanism (granzyme and/or perforin
mediated as measured by CD107a expression) or an indirect, cytokine
(e.g. IFN-γ) dependent mechanism, or both (Appay et al., 2000;
Appay et al., 2002; Dunham et al., 2006). Studies on HIV-1 speciﬁc
CTL have suggested that senescence (Dagarag et al., 2003) or HIV-1
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could be manifested by impaired cytolytic function with little or no
effect on cytokine (IFN-γ) production capacity. Our data show that
SIV Nef-mediated downregulation of MHC class I could diminish the
antiviral capacity of SIV-speciﬁc CTL with no effect on the induction of
either IFN-γ or CD107a and suggest that reductions in suppression
cannot be explained by a simple lack of activation model. These data
point to a mechanism of virus control that is independent of IFN-γ,
which is typically measured when analyzing HIV- and SIV-speciﬁc CTL
responses, as well as CTL degranulation, and that CTL clonal variation
in this yet unknown effector function is substantial, and decisive for
control of SIV replication.
Our data raise important questions regarding the relevance of
current CTL assays based on cognate peptide-pulsed APC. It has long
been apparent that evaluating CTL responses using APCs pulsed with
non-physiologic high concentrations of synthetic peptides provide an
at best incomplete picture, and potentially a misleading assessment of
virus-speciﬁc CD8+ T-cell responses (Yang et al., 2003). While these
assays may be very informative with regard to speciﬁcity and
frequency of CTL responses, they do not necessarily estimate antiviral
capacity and should be viewed as only a ﬁrst step in the evaluation of
virus-speciﬁc CTL responses. Notably, our data using virus-infected
APC suggest that this more physiologically appropriate assay also fails
to predict the virus inhibitory potential and, thus, functional capacity
of CTL clones. Our results have important implications for the eval-
uation of vaccine induced T-cell immunity, as well as for attempts to
correlate CTL responses with clinical outcomes in HIV- or SIV-infected
long-term non-progressors and elite controllers (reviewed in Walker
and Burton (2008)).
Materials and methods
Generation of SIV Gag181–189CM9-speciﬁc CD8
+ and autologous CD4+
T-cell clones
CTL clones speciﬁc to the Mamu-A⁎01-restricted SIV Gag181–
189CM9 epitope (CM9) (O'Connor et al., 2003) were isolated from an
Indian rhesus macaque, Macaca mulatta, chronically infected with
SIVmac239 as described previously (Andersen et al., 2007). Brieﬂy,
lymphocytes were stimulated for 1 week with irradiated autologous
PBMC pulsed with CM9 peptide (SynPep Corp., Dublin, CA). The
cultures were restimulated weekly with CM9 peptide-pulsed and
irradiated autologous PBMC in the presence of recombinant human IL-
2 (50 IU/mL: NIH AIDS Research and Reference Reagent Program,
Germantown, MD). Following 2 rounds of stimulation, the CM9-
speciﬁc CTL were cloned by limiting dilution and maintained
essentially as described in Riddell and Greenberg (1990) and Berger
et al. (2001) using bi-weekly anti-CD3 monoclonal antibody (mAb)
(30 ng/mL; clone SP34-2; BD Biosciences, San Diego, CA, USA)
stimulation with irradiated human PBMC and human Epstein–Barr
virus transformed B-cell lines (TM B-LCL; kindly provided by Drs. S.R.
Riddell and P.D. Greenberg, FHCRC, Seattle, WA) as feeder cells, but
without anti-CD28 mAb stimulation. APC and feeder cells were
irradiated in a Mark I 137Cs γ-irradiator (Shepherd and Associates, San
Fernando, CA) at 6000 and 12,500 rad for PBMC and TM B-LCL,
respectively. Positive wells were tested for antigen speciﬁcity by ﬂow
cytometry using ICS for IFN-γ production and by staining with a CM9
peptide/MHC-tetramer (Beckman Coulter, Miami, FL).
Autologous CD4+ T-cell clones were generated as described
(Andersen et al., 2007). Brieﬂy, highly enriched CD4+ T cells were
isolated by negative selection usingMiltenyi LD columns and anti-CD8
microbeads followed by positive selection usingMS columns and anti-
CD4microbeads (Miltenyi Biotec Inc., Auburn, CA). CD4+ T-cell clones
were obtained after 2-week expansion in limiting dilution cultures
containing irradiated human PBMC, IL-2 and anti-CD3 mAb and
maintained as described above for CD8+ T-cell clones. Animal carewas according to the guidelines of the Committee on the Care and Use
of Laboratory Animals of the Institute of Laboratory Animal Resources,
National Research Council, and the Health and Human Services
guidelines “Guide for the Care and Use of Laboratory Animals”
(National Research Council, 1996, National Academy Press, Washing-
ton, D.C.), under an Institutional Animal Care and Use Committee
approved protocol.
Virus stocks
SIVs used in this study were derived from the plasmid molecular
clone pSIV239spxﬂ (a kind gift of Ronald Desrosiers, New England
Primate Research Center, HarvardMedical School, Southborough, MA)
SIVmac239 (Genbank accession no. M33262.1). These were SIVmac239
Nef/open (WT), SIVmac239 Nef/stop (stop; truncated Nef mutant)
(Kestler et al., 1990; Kestler et al., 1991) and three other SIVmac239
mutant viruses constructed by PCR-mediated overlap extension
(Horton et al., 1990): Nef/Y223F (Y223F), pSIV239spxﬂ with a A-to-T
change at nucleotide (nt) 10,015 resulting in a tyrosine (Y) to
phenylalanine (F) change in Nef codon 223; Nef/G2V (G2V),
pSIV239spxﬂ with a G-to-T change at nt 9352 resulting in a glycine
(G) to valine (V) change in Nef codon 2; and Nef/RR137-138AA
(RR-AA), pSIV239spxﬂ with a pair of AG-to-GC changes at nts 9756/7
and 9759/60 resulting in arginine (R) to alanine (A) changes in Nef
codons 137 and 138 (Schindler et al., 2004). Virus stockswere produced
by transfection of HEK293T cells with WT or mutant SIVmac239 using
TransIt 293 reagent (Mirus Corporation, Madison, WI) according to the
manufacturer's recommendations. HEK293T cells were maintained in
high glucose or Dulbecco modiﬁed Eagle medium supplemented with
10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 50 U of
penicillin per mL and 50 μg of streptomycin per mL (Invitrogen corp.,
Carlsbad, CA, USA).
Infection of CD4+ T cells with SIVmac239
A clonal population of CD4+ T cells was activated with anti-CD3
mAb (T-25 ﬂask-bound: 5 μg/mL) and IL-2 (50 IU/mL) for 48 h and
infected by incubating with aliquots of virus stock for 2–3 h using the
Viromag magnetofection reagents with a ratio of 7.5 μL of beads per
mL of clariﬁed transfection supernatant according to the manufac-
turer's recommendation (OzBiosciences, Marseille, France). Virus
stocks with ∼1×109 viral RNA copies Eq/mL in a volume of 250 μL
were added per 1×106 CD4+ Tcells. Incubations were carried out on a
magnetic plate at 37 °C in a humidiﬁed atmosphere of 5% CO2 and
the virus-exposed CD4+ T cells washed twice with PBS to remove
residual non-incorporated viral material prior to use in assays.
In vitro viral replication inhibition assay
Virus replication inhibition assays were set up as described
previously (Minang et al., 2008). CD4+ T cells were freshly infected
with either WT or mutant SIV, plated at 5×105 cells per well in 24-
well plates and co-cultured with autologous CTL clones speciﬁc to the
SIV Gag CM9 epitope at a CD8+:CD4+ T-cell ratio of 1:1. Uninfected
and SIV-infected CD4+ T cells were cultured without CTL effectors at
1×106 cells per well as negative and positive controls, respectively, for
virus infectivity. The cultures were maintained for 7 to 9 days with
IL-2 addition every 2–3 days at a ﬁnal concentration of 50 IU/mL.
Intracellular staining for SIV Gag p27 expression by virus-infected CD4+
T cells
Staining for surface CD4, MHC class I and intracellular SIV Gag p27
expression was performed to assess the levels of SIV infection at
different time points post infection (PI). All antibodies were obtained
from BD Biosciences (San Diego, CA, USA) unless otherwise indicated.
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mouse sera, 0.05% sodium azide) and stained with antihuman-CD4-
PerCP-Cy5.5 (clone L200) and anti-HLA-ABC-PE (clone G46-2.6)
conjugated mAbs. Cells were incubated for 30 min at 4 °C, washed
with sterile PBS and then ﬁxed with 4% paraformaldehyde (PFA),
500 μL/sample tube for 30 min at 4 °C. The cells were permeabilized
(PBS, 0.1% saponin, 1% rat sera, 1% mouse sera and 0.05% sodium
azide), 1 mL/sample tube for 5 min, washed (0.1% saponin in PBS) and
incubated with FITC conjugated anti-SIV Gag p27 mAb (Clone 55-
2F12, NIH AIDS Research and Reference Reagent Program). A ﬁnal
wash was performed and the cells resuspended in 0.1% PFA. Samples
were acquired on a BD FACSCalibur ﬂow cytometer (BD Biosciences)
and subsequent data analyses performed using FCS Express Version 3
(De Novo Software, Thornhill, Ontario, Canada). Dead cells were
excluded from the analyses based on forward versus side scatter
gating, and at least 100,000 live cell events were collected for
each sample.
Measurement of IFN-γ and CD107a in SIV-speciﬁc CTL clones in response
to peptide-pulsed or SIV-infected target cells
SIV Gag CM9 peptide-pulsed autologous herpesvirus papio-
transformed B-cell lines were used as APC to stimulate SIV Gag
CM9-speciﬁc CTL clones in 5 mL polypropylene tubes. The APC were
pulsed with peptide titrated from 5 μg/mL down to 10−5 μg/mL. The
SIV Gag CM9-speciﬁc CTL clones were also stimulated with autologous
CD4+ Tcells infected withWT SIV, the Y223F, G2V or Nef/stopmutant
virus. The CD4+ Tcells had been infected for 7 or 8 days prior to use as
APC; in our hands, the incubation period needed to achieve peak
frequencies of SIV Gag p27 expressing (N30%) target cells (Minang et
al., 2008). A CD8+:CD4+ T-cell ratio of 1:1 with a total of 1×106 cells
in a ﬁnal volume of 0.5 mL per tube was used and non-pulsed auto-
logous B cells or uninfected autologous CD4+ T cells were included as
negative control APC. PE conjugated mAb speciﬁc to the CTL degranu-
lation marker CD107a (LAMP-1) (clone H4A3) was added at the start
of culture as described (Betts et al., 2003). Monensin, 20 μL/test of a
1:20 dilution (Golgi stop™; BD Bioscience), was added after 1 h of
incubation and the cultures incubated for additional 4 h. Cells were
washed, stained for surface CD8 (PerCP-Cy5.5 conjugated antihuman
CD8 mAb (clone SK1)) and intracellular IFN-γ (FITC conjugated
antihuman IFN-γmAb (clone 4S.B3)) expression. Data were acquired
and analyzed as described above.
Viral RNA measurements
To monitor viral replication in vitro, culture supernatant was
collected at deﬁned time points PI and viral RNA extracted from the
supernatant essentially as described previously (Cline et al., 2005).
Viral replication was quantiﬁed using a real time RT PCR assay es-
sentially as described (Cline et al., 2005; Lifson et al., 2001).
Statistical analyses
The means and standard deviations for viral RNA levels were
computed for duplicate wells of two or more experiments for cultures
of virus-infected or uninfected CD4+ T cells alone or co-cultures of
infected CD4+ T cells and autologous virus-speciﬁc CTL. As described
previously (Minang et al., 2008), a CTL clone was arbitrarily con-
sidered to inhibit viral replicationwhen a reduction in viral RNA levels
of at least 1 log was observed, and the frequency of preserved CD4+
T cells as well as eliminated Gag p27 positive cells was at least 2-fold
higher than in cultures of infected cells alone. Differences in geometric
mean ﬂuorescent intensities (GMFI) of surface MHC class I expression
by CD4+ T cells infected with WT SIVmac239 compared with different
Nef mutants were computed using the two-tailed unpaired student's
t test. Statistical signiﬁcance was set at pb0.05.Acknowledgments
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